Tvardi Therapeutics Inc. Ordinary Shares TVRD 深 滬
等待開盤 09-18 09:30:00 美东时间
39.04
+5.210
+15.40%
華盛通- 最 高39.04
- 今 開35.00
- 成交量 13.48万股
- 最 低 34.16
- 昨 收 33.83
- 總市值 3.65亿
- 52周最高 39.04
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 8.1252
- 委 比 87.50%
- 總股本 936.09万
- 歷史最高 1067.292
- 量 比 4.61
- 振 幅 14.43%
- 歷史最低 8.1252
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tvardi Therapeutics GAAP EPS of -$1.00
Tvardi Therapeutics press release (NASDAQ:TVRD): Q2 GAAP EPS of -$1.00. Cash, cash equivalents and short-term investments as of June 30, 2025, were $41.0 million, as compared to $31.6 million as of De...
08-15 04:58
Tvardi Therapeutics Q2 EPS $(1.00) Misses $(0.58) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.58) by 73.01 percent.
08-15 04:33
Cantor Fitzgerald Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $52
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $52.
07-11 20:00
Coinbase, Datadog, Tvardi, CF, Conagra: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($COIN) ), ( ($DDOG) ), ( ($TVRD) )...
06-14 17:01
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
Piper Sandler Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $78
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $78.
06-12 17:27
Oppenheimer Initiates Coverage On Tvardi Therapeutics with Outperform Rating, Announces Price Target of $65
Oppenheimer analyst Jay Olson initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces Price Target of $65.
05-21 23:13
Tvardi Therapeutics Q1 EPS $(3.22) Misses $(0.31) Estimate, Sales $2.57M Up From $2.13M YoY
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.31) by 938.71 percent. This is a 84.09 percent increase over losses of $(20.24) per
05-14 13:48
